Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SciSparc Ltd. ( (SPRC) ) just unveiled an update.
On December 2, 2025, SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., has signed a non-binding term sheet to acquire a 55% stake in an Israeli quantum computing bio data company. This acquisition aims to leverage quantum computing for enhanced clinical analytics, potentially transforming medical research and development. The deal is subject to due diligence and regulatory approvals, and its completion could significantly impact SciSparc’s operations by integrating advanced quantum technologies into its pharmaceutical research.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based pharmaceuticals. Through its majority-owned subsidiary, NeuroThera Labs Inc., SciSparc is engaged in drug development programs targeting central nervous system disorders such as Tourette syndrome, Alzheimer’s disease, and autism spectrum disorder. The company also has a stake in a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 5,321,644
Technical Sentiment Signal: Sell
Current Market Cap: $2.98M
Learn more about SPRC stock on TipRanks’ Stock Analysis page.